Riximyo for Non-Hodgkin lymphoma
Quick answer: Riximyo is used for Non-Hodgkin lymphoma as part of a anti-cd20 monoclonal antibody (rituximab biosimilar) treatment regimen. Chimeric monoclonal antibody binding CD20 on B-lymphocytes, causing B-cell depletion via ADCC and complement-mediated lysis The specific dosing for Non-Hodgkin lymphoma is determined by your prescriber based on individual factors.
Why is Riximyo used for Non-Hodgkin lymphoma?
Riximyo belongs to the Anti-CD20 monoclonal antibody (rituximab biosimilar) class. Chimeric monoclonal antibody binding CD20 on B-lymphocytes, causing B-cell depletion via ADCC and complement-mediated lysis This action makes it useful for treating or managing Non-Hodgkin lymphoma in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Riximyo is the right choice for a specific patient depends on the type and severity of Non-Hodgkin lymphoma, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Non-Hodgkin lymphoma
Common adult dosing range: 375 mg/m2 IV (oncology); 1000 mg IV x2 (RA). The actual dose for Non-Hodgkin lymphoma depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Riximyo medicine page.
What to expect
Riximyo treatment for Non-Hodgkin lymphoma typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Non-Hodgkin lymphoma
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Riximyo is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Anti-CD20 monoclonal antibody (rituximab biosimilar) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Riximyo
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Riximyo full prescribing information · All Anti-CD20 monoclonal antibody (rituximab biosimilar) alternatives
Frequently asked questions
How effective is Riximyo for Non-Hodgkin lymphoma?
Effectiveness varies by individual response, dose, and severity. Riximyo is one of several treatment options for Non-Hodgkin lymphoma, supported by clinical evidence within the anti-cd20 monoclonal antibody (rituximab biosimilar) class. Discuss expected response with your prescriber.
How long do I need to take Riximyo for Non-Hodgkin lymphoma?
Treatment duration depends on the nature of Non-Hodgkin lymphoma — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Riximyo when used for Non-Hodgkin lymphoma?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Riximyo for Non-Hodgkin lymphoma?
Yes. Multiple medicines and non-drug options exist for Non-Hodgkin lymphoma. Alternatives within the anti-cd20 monoclonal antibody (rituximab biosimilar) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.